200 related articles for article (PubMed ID: 25444812)
1. Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy.
Miller E; Spadaccia M; Sabado R; Chertova E; Bess J; Trubey CM; Holman RM; Salazar A; Lifson J; Bhardwaj N
Vaccine; 2015 Jan; 33(2):388-95. PubMed ID: 25444812
[TBL] [Abstract][Full Text] [Related]
2. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y
J Virol; 2017 May; 91(9):. PubMed ID: 28202751
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection.
Lu W; Arraes LC; Ferreira WT; Andrieu JM
Nat Med; 2004 Dec; 10(12):1359-65. PubMed ID: 15568033
[TBL] [Abstract][Full Text] [Related]
4. Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy.
Sabado RL; Miller E; Spadaccia M; Vengco I; Hasan F; Bhardwaj N
J Vis Exp; 2013 Aug; (78):. PubMed ID: 23928481
[TBL] [Abstract][Full Text] [Related]
5. Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection.
Whiteside TL; Piazza P; Reiter A; Stanson J; Connolly NC; Rinaldo CR; Riddler SA
Clin Vaccine Immunol; 2009 Feb; 16(2):233-40. PubMed ID: 19038780
[TBL] [Abstract][Full Text] [Related]
6. A dendritic cell targeted vaccine induces long-term HIV-specific immunity within the gastrointestinal tract.
Ruane D; Do Y; Brane L; Garg A; Bozzacco L; Kraus T; Caskey M; Salazar A; Trumpheller C; Mehandru S
Mucosal Immunol; 2016 Sep; 9(5):1340-52. PubMed ID: 26732678
[TBL] [Abstract][Full Text] [Related]
7. PolyICLC Exerts Pro- and Anti-HIV Effects on the DC-T Cell Milieu In Vitro and In Vivo.
Aravantinou M; Frank I; Hallor M; Singer R; Tharinger H; Kenney J; Gettie A; Grasperge B; Blanchard J; Salazar A; Piatak M; Lifson JD; Robbiani M; Derby N
PLoS One; 2016; 11(9):e0161730. PubMed ID: 27603520
[TBL] [Abstract][Full Text] [Related]
8. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.
Rapoport AP; Aqui NA; Stadtmauer EA; Vogl DT; Xu YY; Kalos M; Cai L; Fang HB; Weiss BM; Badros A; Yanovich S; Akpek G; Tsao P; Cross A; Mann D; Philip S; Kerr N; Brennan A; Zheng Z; Ruehle K; Milliron T; Strome SE; Salazar AM; Levine BL; June CH
Clin Cancer Res; 2014 Mar; 20(5):1355-65. PubMed ID: 24520093
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes.
Niu L; Termini JM; Kanagavelu SK; Gupta S; Rolland MM; Kulkarni V; Pavlakis GN; Felber BK; Mullins JI; Fischl MA; Stone GW
Vaccine; 2011 Mar; 29(11):2110-9. PubMed ID: 21241732
[TBL] [Abstract][Full Text] [Related]
10. Presentation of exogenous whole inactivated simian immunodeficiency virus by mature dendritic cells induces CD4+ and CD8+ T-cell responses.
Frank I; Santos JJ; Mehlhop E; Villamide-Herrera L; Santisteban C; Gettie A; Ignatius R; Lifson JD; Pope M
J Acquir Immune Defic Syndr; 2003 Sep; 34(1):7-19. PubMed ID: 14501788
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.
Migliorini D; Dutoit V; Allard M; Grandjean Hallez N; Marinari E; Widmer V; Philippin G; Corlazzoli F; Gustave R; Kreutzfeldt M; Blazek N; Wasem J; Hottinger A; Koka A; Momjian S; Lobrinus A; Merkler D; Vargas MI; Walker PR; Patrikidou A; Dietrich PY
Neuro Oncol; 2019 Jul; 21(7):923-933. PubMed ID: 30753611
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.
Andrés C; Plana M; Guardo AC; Alvarez-Fernández C; Climent N; Gallart T; León A; Clotet B; Autran B; Chomont N; Gatell JM; Sánchez-Palomino S; García F
J Virol; 2015 Sep; 89(18):9189-99. PubMed ID: 26109727
[TBL] [Abstract][Full Text] [Related]
13. The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook.
Mohamed H; Miller V; Jennings SR; Wigdahl B; Krebs FC
J Immunol Res; 2020; 2020():9470102. PubMed ID: 32537473
[TBL] [Abstract][Full Text] [Related]
14. Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial.
Saxena M; Sabado RL; La Mar M; Mohri H; Salazar AM; Dong H; Correa Da Rosa J; Markowitz M; Bhardwaj N; Miller E
Front Immunol; 2019; 10():725. PubMed ID: 31024557
[No Abstract] [Full Text] [Related]
15. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.
Okada H; Kalinski P; Ueda R; Hoji A; Kohanbash G; Donegan TE; Mintz AH; Engh JA; Bartlett DL; Brown CK; Zeh H; Holtzman MP; Reinhart TA; Whiteside TL; Butterfield LH; Hamilton RL; Potter DM; Pollack IF; Salazar AM; Lieberman FS
J Clin Oncol; 2011 Jan; 29(3):330-6. PubMed ID: 21149657
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of aldrithiol-2-inactivated preparations of HIV type 1 subtypes A, B, and D as reagents to monitor T cell responses.
Rutebemberwa A; Bess JW; Brown B; Arroyo M; Eller M; Slike B; Polonis V; McCutchan F; Currier JR; Birx D; Robb M; Marovich M; Lifson JD; Cox JH
AIDS Res Hum Retroviruses; 2007 Apr; 23(4):532-42. PubMed ID: 17506610
[TBL] [Abstract][Full Text] [Related]
17. A dendritic cell-based vaccine for treating HIV infection: background and preliminary results.
Andrieu JM; Lu W
J Intern Med; 2007 Feb; 261(2):123-31. PubMed ID: 17241177
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.
Mehrotra S; Britten CD; Chin S; Garrett-Mayer E; Cloud CA; Li M; Scurti G; Salem ML; Nelson MH; Thomas MB; Paulos CM; Salazar AM; Nishimura MI; Rubinstein MP; Li Z; Cole DJ
J Hematol Oncol; 2017 Apr; 10(1):82. PubMed ID: 28388966
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity.
Trumpfheller C; Longhi MP; Caskey M; Idoyaga J; Bozzacco L; Keler T; Schlesinger SJ; Steinman RM
J Intern Med; 2012 Feb; 271(2):183-92. PubMed ID: 22126373
[TBL] [Abstract][Full Text] [Related]
20. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial.
Everson RG; Hugo W; Sun L; Antonios J; Lee A; Ding L; Bu M; Khattab S; Chavez C; Billingslea-Yoon E; Salazar A; Ellingson BM; Cloughesy TF; Liau LM; Prins RM
Nat Commun; 2024 May; 15(1):3882. PubMed ID: 38719809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
